Discover undervalued stocks with Eulerpool.

Subscribe for $2

Xencor Stock XNCR

Price

0
Today +/-
-0
Today %
-0 %

Xencor stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Xencor stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Xencor stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Xencor stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Xencor's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Xencor Stock Price History

DateXencor Price
9/24/20250 undefined
9/24/202510.48 undefined
9/23/202510.33 undefined
9/22/202510.73 undefined
9/19/202510.30 undefined
9/18/20259.92 undefined
9/17/20259.44 undefined
9/16/20258.63 undefined
9/15/20258.50 undefined
9/12/20258.61 undefined
9/11/20258.57 undefined
9/10/20258.37 undefined
9/9/20258.33 undefined
9/8/20258.42 undefined
9/5/20258.62 undefined
9/4/20258.38 undefined
9/3/20258.46 undefined
9/2/20258.52 undefined
8/29/20258.14 undefined
8/28/20258.06 undefined
8/27/20258.02 undefined

Xencor Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Xencor, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Xencor from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Xencor’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Xencor. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Xencor’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Xencor’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Xencor’s growth potential.

Xencor Revenue, EBIT and net profit per share

DateXencor RevenueXencor EBITXencor Net Income
2030e587.82 M undefined0 undefined32.91 M undefined
2029e379.36 M undefined-117.01 M undefined-57.85 M undefined
2028e201.81 M undefined-234.04 M undefined-148.49 M undefined
2027e152.82 M undefined-219.93 M undefined-168.34 M undefined
2026e125.07 M undefined-234.87 M undefined-191.18 M undefined
2025e136.25 M undefined-189.14 M undefined-169.5 M undefined
2024110.49 M undefined-178.41 M undefined-232.62 M undefined
2023174.62 M undefined-132.36 M undefined-133.13 M undefined
2022164.6 M undefined-82.5 M undefined-55.2 M undefined
2021275.1 M undefined43.8 M undefined82.6 M undefined
2020122.7 M undefined-76.8 M undefined-69.3 M undefined
2019156.7 M undefined13.8 M undefined26.9 M undefined
201840.6 M undefined-79.4 M undefined-70.4 M undefined
201746.2 M undefined-43.1 M undefined-38.5 M undefined
2016109 M undefined44 M undefined45.1 M undefined
201527.8 M undefined-18.3 M undefined-17.6 M undefined
20149.5 M undefined-16.5 M undefined-16.4 M undefined
201310.2 M undefined-10.5 M undefined84.5 M undefined
20129.5 M undefined-6.2 M undefined-8.6 M undefined
20116.8 M undefined-9.5 M undefined-11.2 M undefined

Xencor Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
69109271094640156122275164174110136125152201379587
-50.0011.11-10.00200.00303.70-57.80-13.04290.00-21.79125.41-40.366.10-36.7823.64-8.0921.6032.2488.5654.88
--------------------
00000000000000000000
-11-884-16-1745-38-7026-6982-55-133-232-169-191-168-148-5732
--27.27-1,150.00-119.056.25-364.71-184.4484.21-137.14-365.38-218.84-167.07141.8274.44-27.1613.02-12.04-11.90-61.49-156.14
27.427.415.631.43942.446.853.958.557.260.559.760.565.04000000
- - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Xencor Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Xencor is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20112012201320142015201620172018201920202021202220232024
                           
14.52.37854.696.4130.1224.1294.4529.8603334.1623.1593.73497.78
00.40.1308.61.110.221.623.966.42923.7460.85
000000080050000000
00000000000000
0.10.20.10.11.22.95.610.46.510.723.923.318.1418.98
14.62.978.257.797.6141.6230.8315.8558.4637.6424.4675.4635.6577.6
0.40.30.30.92.33.17.111.825.232.36093.6100.1298.14
000096.9273.3139.2236.171.517.1331.758.2209.72256.83
0000001.60.80.405000
7.38.58.89.11010.411.11214.41616.518.518.6618.49
00000000000000
0.10.10.10.10.10.10.30.30.30.20.70.61.030.89
7.88.99.210.1109.3286.9159.3261111.865.6413.9170.9329.53374.34
22.411.887.467.8206.9428.5390.1576.8670.2703.2838.3846.3965.14951.95
                           
146.8146.80.30.30.40.50.50.60.60.60.60.60.610.7
000.30.30.420.550.570.850.890.941.021.071.131.38
-158.7-167.3-227.6-244-261.6-238-252.9-323.3-296.4-365.7-283.1-338.3-471.42-704.04
0000-0.5-1.4-1.8-11.20.1-1.5-71.29-0.66
00000000000000
-10.9-19.573.559.3162.4314316.5521.7593.3572.5733.5727.4661.75677.61
1.81.32.61.76.43.96.93.810.291410.113.9116.76
0.81.31.42.33.66.75.59.711.219.519.423.42722.23
5.11.93.42.333.495.760.340.445.292.637.330.35.290
18.520.9000000000000
00000000000027.7148.45
26.225.47.46.343.4106.372.753.966.6121.170.763.873.9187.43
000000000000161.77115.16
00000000000000
7.15.76.32.318.31.11.210.59.73454.967.3675.33
7.15.76.32.318.31.11.210.59.73454.9229.13190.49
33.331.113.78.644.4114.673.855.177.1130.8104.7118.7303.05277.92
22.411.687.267.9206.8428.6390.3576.8670.4703.3838.2846.1964.8955.53
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Xencor provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Xencor's financial health and stability.

Assets

Xencor's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Xencor must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Xencor after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Xencor's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-11-8-60-16-1745-38-7026-6982-55-126
00001123457811
0000000000000
6-53-83638-14-33548-10248166
22504111830415941327087
0000000000000
0000000000000
-1-11-5-212695-33-7964-5-162485
-1-1-1-2-3-3-7-9-11-13-15-43-21
-1-1-1-2-185-21431-164-50100-46-119-111
0000-181-21139-155-39113-30-76-89
0000000000000
0000000000000
00900124128326810184355
008201161203254101843526
00-80-7-70-14000020
0000000000000
-2-1275-23-4211924113-20-890
-2.51-12.31-6.74-23.6422.9992.23-40.88-88.9153.33-18.77-32.83-18.9163.86
0000000000000

Xencor stock margins

The Xencor margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xencor. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xencor.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Xencor's sales revenue. A higher gross margin percentage indicates that the Xencor retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Xencor's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Xencor's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Xencor's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Xencor. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Xencor's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Xencor Margin History

Xencor Gross marginXencor Profit marginXencor EBIT marginXencor Profit margin
2030e0 %0 %5.6 %
2029e0 %-30.84 %-15.25 %
2028e0 %-115.97 %-73.58 %
2027e0 %-143.91 %-110.16 %
2026e0 %-187.79 %-152.86 %
2025e0 %-138.82 %-124.41 %
20240 %-161.47 %-210.53 %
20230 %-75.8 %-76.24 %
20220 %-50.12 %-33.54 %
20210 %15.92 %30.03 %
20200 %-62.59 %-56.48 %
20190 %8.81 %17.17 %
20180 %-195.57 %-173.4 %
20170 %-93.29 %-83.33 %
20160 %40.37 %41.38 %
20150 %-65.83 %-63.31 %
20140 %-173.68 %-172.63 %
20130 %-102.94 %828.43 %
20120 %-65.26 %-90.53 %
20110 %-139.71 %-164.71 %

Xencor Stock Sales Revenue, EBIT, Earnings per Share

The Xencor earnings per share therefore indicates how much revenue Xencor has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xencor earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xencor's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xencor’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xencor's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Xencor Revenue, EBIT and net profit per share

DateXencor Sales per ShareXencor EBIT per shareXencor Earnings per Share
2030e9.04 undefined0 undefined0.51 undefined
2029e5.83 undefined0 undefined-0.89 undefined
2028e3.1 undefined0 undefined-2.28 undefined
2027e2.35 undefined0 undefined-2.59 undefined
2026e1.92 undefined0 undefined-2.94 undefined
2025e2.09 undefined0 undefined-2.61 undefined
20241.7 undefined-2.74 undefined-3.58 undefined
20232.89 undefined-2.19 undefined-2.2 undefined
20222.76 undefined-1.38 undefined-0.92 undefined
20214.55 undefined0.72 undefined1.37 undefined
20202.15 undefined-1.34 undefined-1.21 undefined
20192.68 undefined0.24 undefined0.46 undefined
20180.75 undefined-1.47 undefined-1.31 undefined
20170.99 undefined-0.92 undefined-0.82 undefined
20162.57 undefined1.04 undefined1.06 undefined
20150.71 undefined-0.47 undefined-0.45 undefined
20140.3 undefined-0.53 undefined-0.52 undefined
20130.65 undefined-0.67 undefined5.42 undefined
20120.35 undefined-0.23 undefined-0.31 undefined
20110.25 undefined-0.35 undefined-0.41 undefined

Xencor business model

The company Xencor Inc was founded in 1997 and has since become a significant biotechnology company specializing in the development of therapeutic proteins. Xencor's goal is to develop innovative and tailored therapies for the treatment of serious diseases such as cancer and autoimmune diseases. The company is headquartered in Monrovia, California, and employs a growing number of scientists, engineers, and other professionals specialized in the development of new themes and products. Xencor has acquired a variety of patents over the years to protect its intellectual property. Its business model is based on the development of new therapeutics through its proprietary XmAb technology platform, which enables the production of highly specific polyclonal antibodies that can improve the efficiency and safety of disease treatments. Xencor has divided its business activities into various divisions, including the development of immuno-oncology products, autoimmune therapies, and new methods for the therapy of inflammatory bowel diseases. The company has developed a wide range of products, including a new class of therapeutic antibodies that mobilize and strengthen patients' own immune system to fight cancer cells. By combining these antibodies with other therapies, the effectiveness of the treatment can be further increased. In the autoimmune diseases division, Xencor has developed new therapeutics to better regulate patients' immune system and treat dangerous autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, or lupus. Another focus of the company is the development of therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. By developing specific antibodies involved in the inflammatory processes in the intestine, Xencor can contribute to improving the treatment of these conditions. Xencor aims to accelerate the development of new therapeutics while improving their efficacy and safety. With the help of its proprietary XmAb technology platform, the company is able to develop new drugs faster and more effectively than conventional methods. Through the combination of technology, research and development, and a high level of commitment, Xencor pursues its vision and has successfully established itself as one of the leading companies in the biotechnology industry. Xencor is one of the most popular companies on Eulerpool.com.

Xencor SWOT Analysis

Strengths

Xencor Inc possesses several key strengths that contribute to its success in the biopharmaceutical industry. These include:

  • Strong Research and Development Capabilities: Xencor Inc has a highly skilled and experienced research team that constantly drives innovation in the development of novel antibody therapeutics.
  • Robust Intellectual Property Portfolio: The company owns a substantial number of patents and intellectual property rights, providing a competitive advantage and protecting its innovative products.
  • Strategic Partnerships: Xencor Inc has established collaborations with major pharmaceutical companies, which provides access to additional resources, expertise, and potential commercialization opportunities.
  • Diversified Product Pipeline: The company has a diversified pipeline of potential drug candidates targeting different indications, reducing risk and maximizing potential revenue streams.

Weaknesses

Despite its strengths, Xencor Inc faces certain weaknesses that may hinder its growth and competitiveness:

  • Dependence on Partnerships: The company heavily relies on collaborations and licensing agreements for the development and commercialization of its products, which may limit its control over decision-making and financial returns.
  • Limited Marketing and Distribution Capabilities: Xencor Inc lacks comprehensive in-house marketing and distribution capabilities, making it reliant on partners for successful product launches and reaching target markets effectively.
  • Relatively Small Market Presence: Compared to larger competitors, Xencor Inc has a relatively smaller market presence, which may affect its ability to capture significant market share and compete with well-established industry players.

Opportunities

Xencor Inc has several opportunities for growth and expansion:

  • Growing Demand for Biopharmaceuticals: The increasing prevalence of various diseases, along with advancements in biotechnology, presents a significant opportunity for Xencor Inc to develop and commercialize innovative therapies to address unmet medical needs.
  • Expansion into International Markets: The company can explore new markets globally, leveraging strategic partnerships or establishing subsidiaries to gain access to untapped patient populations and increase revenue streams.
  • Advancements in Technology: Technological advancements in antibody engineering and drug delivery systems offer the potential for Xencor Inc to develop next-generation therapeutics with improved efficacy, safety, and patient outcomes.

Threats

Xencor Inc faces certain threats that could impact its operations and market position:

  • Intense Competition: The biopharmaceutical industry is highly competitive, with numerous companies competing for market share. Xencor Inc may face challenges from both established pharmaceutical giants and smaller biotech firms.
  • Regulatory and Compliance Risks: The industry is subject to stringent regulatory requirements and evolving compliance standards. Non-compliance or delays in obtaining regulatory approvals can significantly impact the company's ability to market and sell its products.
  • Uncertain Economic Climate: Economic downturns and fluctuations in healthcare spending can affect the affordability and demand for biopharmaceutical products, potentially impacting Xencor Inc's financial performance.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Xencor Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Xencor historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Xencor shares outstanding

The number of shares was Xencor in 2024 — This indicates how many shares 65.041 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Xencor earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Xencor's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Xencor’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Xencor's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Xencor.

Xencor latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.73 -0.41  (44.19 %)2025 Q2
3/31/2025-0.61 -0.66  (-7.54 %)2025 Q1
12/31/2024-0.8 -0.62  (22.47 %)2024 Q4
9/30/2024-1 -0.71  (29.05 %)2024 Q3
6/30/2024-0.89 -1.07  (-19.62 %)2024 Q2
3/31/2024-0.81 -1.11  (-37.38 %)2024 Q1
12/31/2023-0.09 -0.31  (-243.68 %)2023 Q4
9/30/2023-0.74 -0.4  (46.02 %)2023 Q3
6/30/2023-0.81 -0.37  (54.5 %)2023 Q2
3/31/2023-0.68 -1.02  (-50.87 %)2023 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Xencor stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

73

👫 Social

83

🏛️ Governance

52

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees58
Percentage of women in management
Percentage of Asian employees34
Share of Asian management
Percentage of Hispanic/Latino employees18
Hispano/Latino Management share
Percentage of Black employees3
Black Management Share
Percentage of white employees42
White Management Share100
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Xencor shareholders

%
Name
Stocks
Change
Date
16.41143 % BlackRock Institutional Trust Company, N.A.10,674,208-68,4326/30/2025
16.18560 % PRIMECAP Management Company10,527,322766,3106/30/2025
13.23699 % The Vanguard Group, Inc.8,609,509725,9086/30/2025
9.44748 % EcoR1 Capital, LLC6,144,76706/30/2025
5.86952 % State Street Global Advisors (US)3,817,610133,8956/30/2025
5.61736 % T. Rowe Price Associates, Inc.3,653,607-176,2416/30/2025
4.21292 % BVF Partners L.P.2,740,14106/30/2025
3.77012 % TCG Crossover Management, LLC2,452,13806/30/2025
3.69440 % RTW Investments L.P.2,402,88306/30/2025
2.73760 % Dimensional Fund Advisors, L.P.1,780,57043,1826/30/2025
1
2
3
4
5
...
10

Xencor Executives and Management Board

Dr. Bassil Dahiyat

(53)
Xencor President, Chief Executive Officer, Founder and Director (since 1997)
Compensation 7.97 M

Dr. Nancy Valente

(65)
Xencor Executive Vice President, Chief Development Officer (since 2022)
Compensation 5.17 M

Dr. John Desjarlais

(59)
Xencor Executive Vice President - Research, Chief Scientific Officer (since 2023)
Compensation 3.21 M

Ms. Celia Eckert

(52)
Xencor Senior Vice President, General Counsel, Corporate Secretary
Compensation 2.02 M

Dr. Barbara Klencke

(67)
Xencor Independent Director
Compensation 467,345
1
2
3

Most common questions regarding Xencor

What values and corporate philosophy does Xencor represent?

Xencor Inc represents values and a corporate philosophy focused on advancing breakthrough medicines for patients. With a commitment to innovation and cutting-edge technology, Xencor is dedicated to transforming the treatment of serious diseases. The company's core values encompass scientific excellence, integrity, collaboration, and resilience. By leveraging its proprietary XmAb® technology, Xencor aims to create next-generation antibody therapeutics that have the potential to deliver improved outcomes for patients. With a robust pipeline and strong research capabilities, Xencor strives to make a meaningful impact in the field of biotechnology, driving advancements in human health.

In which countries and regions is Xencor primarily present?

Xencor Inc is primarily present in the United States.

What significant milestones has the company Xencor achieved?

Xencor Inc, a leading biopharmaceutical company, has achieved several significant milestones since its inception. The company successfully advanced its proprietary XmAb® technology, bringing innovative antibody therapeutics to market. Xencor Inc also forged strategic collaborations with renowned pharmaceutical companies, facilitating the development and commercialization of novel therapies. The company's dedication to research and development resulted in the initiation of multiple clinical trials, highlighting its commitment to addressing unmet medical needs. Xencor Inc's milestones include securing regulatory approvals and advancing therapeutic candidates across a range of diseases, solidifying its position in the biopharmaceutical industry. With its impactful achievements, Xencor Inc continues to drive innovation and improve patient outcomes globally.

What is the history and background of the company Xencor?

Xencor Inc, founded in 1997, is a renowned biopharmaceutical company based in Monrovia, California. With a focus on developing monoclonal antibody therapeutics, Xencor has become a leader in the field of immuno-oncology and autoimmune diseases. The company employs its proprietary XmAb® technology platform, allowing for enhanced antibody engineering and development. Xencor has established numerous strategic partnerships with renowned pharmaceutical companies, leveraging its expertise to create innovative treatments. Recognized for its rigorous scientific approach and commitment to pioneering medicine, Xencor continues to advance its pipeline for potential therapies, aiming to improve patient outcomes in various disease areas.

Who are the main competitors of Xencor in the market?

The main competitors of Xencor Inc in the market include big pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche. These companies are also engaged in the development and commercialization of biopharmaceutical products in various therapeutic areas. Xencor Inc, a leading clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies for treating severe and life-threatening diseases.

In which industries is Xencor primarily active?

Xencor Inc is primarily active in the biotechnology industry.

What is the business model of Xencor?

Xencor Inc is a biopharmaceutical company that specializes in the discovery, development, and commercialization of engineered monoclonal antibodies and cytokines for the treatment of severe and life-threatening diseases. Its business model revolves around leveraging its proprietary XmAb® technology platform to engineer superior antibodies with enhanced therapeutic potential. By partnering with pharmaceutical companies, Xencor aims to advance its drug candidates through clinical development and regulatory approval, ultimately aiming to bring innovative and transformative therapies to patients in need. With a focus on innovation, Xencor continues to drive research and development efforts in the field of antibody engineering, positioning itself as a leading player in the biopharmaceutical industry.

What is the P/E ratio of Xencor 2025?

The P/E ratio cannot be calculated for Xencor at the moment.

What is the P/S ratio of Xencor 2025?

The P/S cannot be calculated for Xencor currently.

What is the Quality Investing of Xencor?

The Quality Investing for Xencor is 4/10.

What is the revenue of Xencor 2025?

The expected Xencor revenue is 136.25 M USD.

How high is the profit of Xencor 2025?

The expected Xencor profit is -169.5 M USD.

What is the business model of Xencor

Xencor Inc is a biopharmaceutical company specializing in the development of protein-based therapeutics and antibodies for the treatment of cancer and autoimmune diseases. The company follows an innovative business model based on proprietary protein engineering technologies. Xencor's product range includes a wide variety of therapeutics and antibodies specifically tailored to the needs of patients with serious diseases. The company's key products include: 1. XmAb Program - A family of antibody platforms based on Xencor's proprietary protein design technology. This platform allows researchers to develop antibodies with improved efficacy and safety. The program has the potential to target a wide range of molecules and therefore serve a broad spectrum of indications. 2. Bispecific Platform - A technology that enables the development of antibodies capable of simultaneously binding to two different target molecules on the surface of cancer cells or immune cells. These bispecifics allow for targeted destruction of cancer cells or activation of immune cells and can therefore offer unique therapeutic possibilities for cancer patients. 3. Xtend-Fc Technology - A platform based on the extension of the half-life of biological drugs. By extending the half-life of therapeutics, they can be administered less frequently, improving patients' quality of life and treatment adherence. The company operates two main business areas: in-house research and partnerships. In the field of in-house research, Xencor focuses on the development of innovative therapeutics that are either marketed on their own or go into product development in partnership with leading pharmaceutical companies. Xencor has an impressive list of collaboration partners where the company provides its technology platforms to jointly develop innovative therapeutics. Key partnerships include Novartis, Merck, Amgen, and Morphosys. Another source of revenue for Xencor is the licensing of its technology platforms and product candidates to other pharmaceutical companies. The company has entered into several licensing agreements with international pharmaceutical and biotech companies, giving it access to new technologies and markets and enabling the global distribution of its products. Xencor Inc has a clear focus on the development of protein-based therapeutics and antibodies. The company pursues a diversified business strategy that focuses on the development of innovative products and platform technologies, as well as collaboration with industry leaders. Through this strategy, Xencor Inc is able to provide patients worldwide with access to a wide range of therapeutics aimed at optimized clinical outcomes and improved safety.

What is the Xencor dividend?

Xencor pays a dividend of 0 USD distributed over payouts per year.

How often does Xencor pay dividends?

The dividend cannot currently be calculated for Xencor or the company does not pay out a dividend.

What is the Xencor ISIN?

The ISIN of Xencor is US98401F1057.

What is the Xencor WKN?

The WKN of Xencor is A1W96L.

What is the Xencor ticker?

The ticker of Xencor is XNCR.

How much dividend does Xencor pay?

Over the past 12 months, Xencor paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xencor is expected to pay a dividend of 0 USD.

What is the dividend yield of Xencor?

The current dividend yield of Xencor is .

When does Xencor pay dividends?

Xencor pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xencor?

Xencor paid dividends every year for the past 0 years.

What is the dividend of Xencor?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xencor located?

Xencor is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xencor kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xencor from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.

When did Xencor pay the last dividend?

The last dividend was paid out on 9/26/2025.

What was the dividend of Xencor in the year 2024?

In the year 2024, Xencor distributed 0 USD as dividends.

In which currency does Xencor pay out the dividend?

The dividends of Xencor are distributed in USD.

All fundamentals about Xencor

Our stock analysis for Xencor Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xencor Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.